580 related articles for article (PubMed ID: 17897631)
1. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
Gehlert DR; Schober DA; Morin M; Berglund MM
Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
[TBL] [Abstract][Full Text] [Related]
2. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?
Iyengar S; Li DL; Simmons RM
J Pharmacol Exp Ther; 1999 May; 289(2):1031-40. PubMed ID: 10215684
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
[TBL] [Abstract][Full Text] [Related]
4. Role of the C terminus in neuropeptide Y Y1 receptor desensitization and internalization.
Holliday ND; Lam CW; Tough IR; Cox HM
Mol Pharmacol; 2005 Mar; 67(3):655-64. PubMed ID: 15576634
[TBL] [Abstract][Full Text] [Related]
5. Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors.
Dautzenberg FM; Neysari S
Pharmacology; 2005 Dec; 75(1):21-9. PubMed ID: 15908753
[TBL] [Abstract][Full Text] [Related]
6. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system.
Pons J; Kitlinska J; Ji H; Lee EW; Zukowska Z
Can J Physiol Pharmacol; 2003 Feb; 81(2):177-85. PubMed ID: 12710532
[TBL] [Abstract][Full Text] [Related]
7. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation.
Sørensen G; Lindberg C; Wörtwein G; Bolwig TG; Woldbye DP
J Neurosci Res; 2004 Sep; 77(5):723-9. PubMed ID: 15352219
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands.
Ziemek R; Brennauer A; Schneider E; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A
Eur J Pharmacol; 2006 Dec; 551(1-3):10-8. PubMed ID: 17027743
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line.
Sheriff S; Ali M; Yahya A; Haider KH; Balasubramaniam A; Amlal H
Mol Cancer Res; 2010 Apr; 8(4):604-14. PubMed ID: 20332211
[TBL] [Abstract][Full Text] [Related]
10. BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.
Dumont Y; Gaudreau P; Mazzuferi M; Langlois D; Chabot JG; Fournier A; Simonato M; Quirion R
Br J Pharmacol; 2005 Dec; 146(8):1069-81. PubMed ID: 16231000
[TBL] [Abstract][Full Text] [Related]
11. PYY preference is a common characteristic of neuropeptide Y receptors expressed in human, rat, and mouse gastrointestinal epithelia.
Holliday ND; Pollock EL; Tough IR; Cox HM
Can J Physiol Pharmacol; 2000 Feb; 78(2):126-33. PubMed ID: 10737675
[TBL] [Abstract][Full Text] [Related]
12. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice.
Kanatani A; Mashiko S; Murai N; Sugimoto N; Ito J; Fukuroda T; Fukami T; Morin N; MacNeil DJ; Van der Ploeg LH; Saga Y; Nishimura S; Ihara M
Endocrinology; 2000 Mar; 141(3):1011-6. PubMed ID: 10698177
[TBL] [Abstract][Full Text] [Related]
13. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
[TBL] [Abstract][Full Text] [Related]
14. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.
Henry M; Ghibaudi L; Gao J; Hwa JJ
Obes Res; 2005 Jan; 13(1):36-47. PubMed ID: 15761161
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5).
Dumont Y; Cadieux A; Doods H; Fournier A; Quirion R
Can J Physiol Pharmacol; 2000 Feb; 78(2):116-25. PubMed ID: 10737674
[TBL] [Abstract][Full Text] [Related]
16. Expression cloning of a human brain neuropeptide Y Y2 receptor.
Gehlert DR; Beavers LS; Johnson D; Gackenheimer SL; Schober DA; Gadski RA
Mol Pharmacol; 1996 Feb; 49(2):224-8. PubMed ID: 8632753
[TBL] [Abstract][Full Text] [Related]
17. Mutagenesis of human neuropeptide Y/peptide YY receptor Y2 reveals additional differences to Y1 in interactions with highly conserved ligand positions.
Akerberg H; Fällmar H; Sjödin P; Boukharta L; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
Regul Pept; 2010 Aug; 163(1-3):120-9. PubMed ID: 20471432
[TBL] [Abstract][Full Text] [Related]
18. Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue.
Tovote P; Meyer M; Beck-Sickinger AG; von Hörsten S; Ove Ogren S; Spiess J; Stiedl O
Regul Pept; 2004 Aug; 120(1-3):205-14. PubMed ID: 15177939
[TBL] [Abstract][Full Text] [Related]
19. Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture.
Abounader R; Elhusseiny A; Cohen Z; Olivier A; Stanimirovic D; Quirion R; Hamel E
J Cereb Blood Flow Metab; 1999 Feb; 19(2):155-63. PubMed ID: 10027771
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptide Y Y1 receptors in the central nucleus of amygdala mediate the anxiolytic-like effect of allopregnanolone in mice: Behavioral and immunocytochemical evidences.
Deo GS; Dandekar MP; Upadhya MA; Kokare DM; Subhedar NK
Brain Res; 2010 Mar; 1318():77-86. PubMed ID: 20059983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
